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Abstract
Cerebral venous thrombosis (CVT) is a potentially
life-threatening condition requiring rapid diagnosis and
urgent treatment. Heparin anticoagulation is the time-hon-
oured treatment, and is advocated in all cases of CVT, irre-
spective of etiology or presence of haemorrhage. The sup-
portive evidence is largely observational; data from ran-
domized placebo-controlled trials shows a nonsignificant
trend favouring heparin. Current practice is to begin heparin
(unfractionated or low-molecular weight) immediately on
confirmation of the diagnosis. Newer anti-thrombotic
agents such as ximelagatran may offer advantages over
heparin and need to be investigated in the treatment of CVT. 
Introduction
Thrombosis of the cerebral veins and sinuses (cere-
bral venous thrombosis, or CVT) has been recognized as a
distinct pathologic entity for over 150 years.1 The disorder
is not infrequently encountered in clinical practice - a busy
inpatient neurology service can typically see at least a few
cases per year. For example, in a large prospective, observa-
tional study across 89 centers, an average of 2.3 CVT
patients were seen at each participating center in a given
year.2 Population-based figures are lacking, but indirect
estimates from autopsy data as well as large clinical series
suggest 3 to 4 cases per million population, with the major-
ity of patients (75%) being women.3 As with other intracra-
nial disorders, our mechanistic understanding of this condi-
tion has been greatly enhanced in the modern era, as imag-
ing techniques (especially magnetic resonance venography
and angiography) have helped revise previous assumptions.
The pathophysiology, clinical spectrum, and diagnostic
approach for CVT have been discussed elsewhere in this
issue. This review focuses on the role of heparin in the man-
agement of CVT patients.
Clinical considerations
Clinical presentation of CVT is notoriously variable,
making a high index of clinical suspicion mandatory.
Neurological manifestations are produced by focal effects
of venous obstruction, including oedema, infarction and
local haemorrhage, as well as by raised intracranial pres-
sure.4 Most patients, therefore, present with headache, with
or without focal deficits. In 10-30% cases an encephalo-
pathic presentation may dominate, which can be clinically
misleading. An identifiable cause or predisposing condition
is found in over 80% of cases.4 The list of possible causes is
long, but they can generally be grouped into infectious (e.g.,
otitis or mastoiditis), mechanical (e.g., trauma or neurosur-
gical procedure), and medical (e.g., hypercoagulable states
or inflammatory bowel disease) etiologies. Prognosis is
generally favourable. In a recent large prospective series of
624 cases, 80% of patients recovered to a modified Rankin
score of 0 or 1 (functional independence); 8% of patients
died, 7% had mild impairments, and 5% remained moder-
ately to severely disabled.2 Thus with accurate diagnosis
and prompt therapy,  majority of patients are able to
approach prior levels of functioning.
An established diagnosis is a prerequisite for treat-
ment. The goal of treatment is to arrest clot propagation;
therefore, diagnosis must be urgently established and thera-
py begun expeditiously. Because of the variable symptoma-
tology, diagnosis may be delayed unless suspected early and
frequently. The investigation of choice is MRI of the brain
with standard sequences (T1, T2, FLAIR), plus cranial MR
venography.5
Treatment is aimed at general measures to relieve
raised intracranial pressure, as well as specific measures tar-
geting the thrombotic process. Unlike in arterial thrombosis,
where clot formation depends on atherosclerotic plaque
inflammation and platelet activity, venous thrombosis
results from activation of the coagulation cascade.
Anticoagulant and anti-thrombotic strategies are therefore
the cornerstone, and there is no pathophysiologic rationale
for the use of anti-platelet agents in CVT.4 Although
endovascular thrombolysis has been increasingly used, anti-
coagulation with heparin remains the time-honoured treat-
ment. Studies are needed to establish the advantage, if any,
of endovascular thrombolysis over heparin, and especially
to identify subsets of patients who may be best treated with
thrombolytic therapy.3 Evidence favouring the use of
heparin is largely circumstantial, and an adequately pow-
ered high-quality randomized clinical trial testing the effica-
cy of heparin against placebo in CVT is still awaited.
Nevertheless, based on available data, the therapy continues
to be the mainstay of CVT management. 
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Pharmacology of heparin
Heparin has been in clinical use for 60 years [6]. It is
a polysaccharide mixture comprising glycosaminoglycans of
varying molecular size that incorporate a unique pentasac-
charide structure binding to and inhibiting anti-thrombin III.
With intravenous administration, anticoagulant effect is rap-
idly achieved. Dosing is variable, and must be adjusted to
maintain the activated partial thromboplastin time (aPTT)
prolonged at 1.5 to 2.0 times the normal laboratory control.
A typical starting regimen is 5,000 units given by IV bolus,
followed by a continuous infusion of 1,000 units per hour,
with subsequent adjustment according to periodic and care-
ful aPTT measurement. Weight-adjusted doses and dosing
nomograms have also been developed.6 Subcutaneous injec-
tion of heparin may also be used, but higher doses are
required. Intravenous administration is the preferred method,
however, as the subcutaneous route is associated with unre-
liable bioavailability and delayed onset of anticoagulant
effects.
Low molecular weight heparin (LMWH) is a more
recent version of heparin that has been available over the
last 20 years. It was developed to minimize the bleeding
complications associated with unfractionated (standard)
heparin. LMWH is prepared by depolymerizing heparin into
lower molecular weight fragments that are approximately
one-third the size of standard heparin. There are clear
advantages in terms of more reliable dose-response pharma-
cokinetics, and a reduced propensity for the platelet inhibi-
tion seen with standard heparin (heparin-induced thrombo-
cytopenia or HIT).7 Because of a more predictable anticoag-
ulant response, laboratory coagulation monitoring is not
needed. Based on uncontrolled as well as placebo-con-
trolled evidence, LMWH is effective in the management of
CVT and can be used as an alternative to unfractionated
heparin.8 However, there has yet to be a study that provides
a head-to-head comparison of LMWH with unfractionated
heparin in this setting. 
Evidence of efficacy
Over the years, the use of heparin in CVT has been
supported by case reports as well as retrospective and
prospective uncontrolled series.9-11 To date, three random-
ized placebo-controlled trials have also examined the effica-
cy of heparin in CVT.3 However, the numbers of patients are
small and there have been methodological limitations. As
the demand for quality medical evidence becomes more
stringent, the absence of an adequately powered clinical
trial addressing this question in a definitive fashion is acute-
ly felt.
Einhaupl and colleagues10 reported a randomized
double-blind trial of 20 patients (10 heparin, 10 placebo)
from Germany in which outcome was assessed by a fresh-
ly-formulated clinical scale of CVT severity. At 3-month
follow-up, 8 of 10 patients in the heparin group had com-
pletely recovered, compared with only 1 of 10 in the place-
bo group (p < 0.01). Although there was no mortality in the
heparin group, 3 patients died in the placebo group. In a
study from Amsterdam, de Bruijn and Stam.8 randomized
60 patients to receive either nardoparin (a low-molecular-
weight heparin) or placebo, and found a greater likelihood
of favourable outcome from nardoparin; however, the dif-
ference between the two groups was not statistically signif-
icant. A third trial reported results of 57 women with peri-
partum CVT randomized to heparin or placebo in India.12
There was a non-significant benefit favouring heparin, but
the result has limited interpretation as CVT diagnosis in this
study was not confirmed by MRI. A pooled analysis of the
German and Dutch trials concluded that anticoagulant treat-
ment of CVT is safe and produces a "potentially important"
reduction in the risk of death or dependency which, howev-
er, does not reach statistical significance.13 Additional trials
are needed to definitively establish the benefit of heparin in
CVT with statistical significance. It has been estimated that
an adequately powered trial that anticipates the previously
observed effect size would need to recruit 300 patients.3
An important conclusion from the available data on
heparin use in CVT is regarding safety. The frequent pres-
ence of oedema and especially haemorrhagic venous infarc-
tion has been a deterrent for many clinicians fearing aggra-
vated intracranial bleeding; indeed, the issue has historical-
ly been somewhat controversial.4 Observations from uncon-
trolled series of heparin-treated CVT patients confirm that
(assuming vigilant monitoring of the aPTT) the risk of
aggravated intracranial bleeding is minimal to none, and
even the presence of haemorrhagic infarction is not a con-
traindication to treatment.3,4 The trial by de Bruijn and
Stam8 for example, included 25 patients with haemorrhagic
infarction who received heparin without adverse effects. It
is now considered standard practice to continue heparin in
the acute phase, followed by oral anticoagulation with war-
farin. Heparin is administered regardless of the etiology of
the thrombosis and is only withheld in case of a general
medical contraindication to heparin such as hypersensitivi-
ty. The optimal duration of treatment with either heparin or
oral anticoagulation remains unclear. Most neurologists
(including our own group) will administer heparin for the
first few days followed by anticoagulation with warfarin for
3-6 months with a target international normalized ratio
(INR) of 2.5.
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Limitations and prospects
Anticoagulation is a potentially difficult therapy
with side-effects that can limit its use. Although the risk of
bleeding complications is minimized with rigorous monitor-
ing and control of the aPTT, the burden of laboratory mon-
itoring is nevertheless costly and cumbersome. In up to 3%
cases, heparin use is also associated with an immune-medi-
ated thrombocytopenia (heparin-induced thrombocytopenia
or HIT)6; the condition is characterized by IgG-mediated
platelet activation and paradoxically creates a prothrombot-
ic state. Treatment is challenging and may require use of
ancrod, a defibrogenating agent prepared from snake
venom. Rarely, hypersensitivity reactions to heparin are
also seen. Novel anti-thrombotic agents are emerging that
may circumvent the limitations of traditional anticoagulants
such as heparin and warfarin.14 Lepriudin and argatroban
are direct thrombin inhibitors that appear to have efficacy in
patients developing heparin-induced thrombocytopenia.
Ximelagatran is also a direct thrombin inhibitor that has
demonstrated safety and efficacy in the management of
venous thromboembolism; it appears likely it will benefit
CVT patients and should be examined in a Phase III clinical
trial. 
References
1. Ribes MF. Des recherches faites sur la phlebite. Revue Medicale Francaise et
Etrangere et Journal de Clinique de l'Hotel-Dieu et de la Charite de Paris
1825; 3:5
2. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis
of cerebral vein and dural sinus thrombosis: results of the International Study
on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664-
70.
3. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005;
352:1791-8.
4. Bousser MG, Barnett HJM. Cerebral venous thrombosis. In: Barnett HJM,
Mohr JP, Stein BM, Yatsu FM (eds.) Stroke: Pathophysiology, Diagnosis and
Management, Churchill Livingstone (New York); 1998:623-7.
5. Lafitte F, Boukobza M, Guichard JP, Hoeffel C, Reizine D, Ille O, Woimant
F, Merland JJ. MRI and MRA for diagnosis and follow-up of cerebral venous
thrombosis (CVT). Clin Radoil 1997; 52:672-9.
6. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R,
Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight
heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, effica-
cy, and safety. Chest 2001; 119(1 Suppl):64S-94S.
7. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-98.
8. deBruijn SF, Stam J. Randomized placebo-controlled trial of anticoagulant
treatment with low-molecular-weight heparin for cerebral sinus thrombosis.
Stroke 1999; 30:484-8.
9. Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis: a
review of 38 cases. Stroke 1985; 16:199-213.
10. Einhaupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M,
Haberl RL, Pfister HW, Schmiedek P. Heparin treatment in sinus venous
thrombosis. Lancet 1991; 338:597-600.
11. Halpern JP, Morris JGL, Driscoll GL. Anticoagulants and cerebral venous
thrombosis. Aust NZ J Med 1984; 14:643-8.
12. Nagaraja D, Rao BSS, Taly AB, Subhash MN. Randomizd controlled trial of
heparin in puerperal cerebral venous/sinus thrombosis. Nimhans J
1995;13:111-5.
13. Stam J, deBruin SF, deVeber G. Anticoagulation for cerebal sinus thrombosis.
Stroke 2003; 34:1054-5.
14. Franvis CW. Direct thrombin inhibitors for treatment of heparin induced
